Thealpha-1 (α1)adrenergic receptor (or adrenoceptor) is aG protein-coupled receptor (GPCR) associated with theGqheterotrimeric G protein. It consists of three highly homologous subtypes,α1A-,α1B-, andα1D-adrenergic. There is no α1C receptor. At one time, there was a subtype known as α1C, but it was found to be identical to the previously discovered α1A receptor subtype.[1] To avoid confusion, naming was continued with the letter D.Catecholamines likenorepinephrine (noradrenaline) andepinephrine (adrenaline) signal through the α1-adrenergic receptors in thecentral andperipheral nervous systems. The crystal structure of the α1B-adrenergic receptor subtype has been determined in complex with the inverse agonist (+)-cyclazosin.[2]
The α1-adrenergic receptor has several general functions in common with theα2-adrenergic receptor, but also has specific effects of its own. α1-receptors primarily mediatesmooth muscle contraction, but have important functions elsewhere as well.[3] Theneurotransmitter norepinephrine has higher affinity for the α1 receptor than does the hormoneadrenaline.
It also induces contraction of the internal urethral sphincter[7] of theurinary bladder,[8][9] although this effect is minor compared to the relaxing effect ofβ2-adrenergic receptors. In other words, the overall effect of sympathetic stimuli on the bladder is relaxation, in order to inhibitmicturition upon anticipation of a stressful event. Other effects on smooth muscle are contraction in:
Uterus (when pregnant): this is minor compared to the relaxing effects of the β2 receptor, agonists of which—notably albuterol/salbutamol—were formerly[citation needed] used to inhibit premature labor.
Activation of α1-adrenergic receptors producesanorexia and partially mediates the efficacy ofappetite suppressants likephenylpropanolamine andamphetamine in the treatment ofobesity.[10] Norepinephrine has been shown to decreasecellular excitability in all layers of thetemporal cortex, including theprimary auditory cortex. In particular, norepinephrine decreasesglutamatergic excitatorypostsynaptic potentials by the activation of α1-adrenergic receptors.[11] Norepinephrine also stimulatesserotonin release by binding α1-adrenergic receptors located on serotonergic neurons in the raphe.[12]α1-adrenergic receptor subtypes increase inhibition in the olfactory system, suggesting a synaptic mechanism for noradrenergic modulation of olfactory driven behaviors.[13]
Activatemitogenic responses and regulate growth and proliferation of many cells
Involved in the detection of mechanical feedback on thehypoglossal motor neurons which allow a long-term facilitation in respiration in response to repeatedapneas.[17]
α1-Adrenergic receptors are members of theG protein-coupled receptor superfamily. Upon activation, aheterotrimeric G protein,Gq, activatesphospholipase C (PLC), which causesphosphatidylinositol to be transformed intoinositol trisphosphate (IP3) anddiacylglycerol (DAG). While DAG stays near the membrane, IP3 diffuses into the cytosol and to find the IP3 receptor on the endoplasmic reticulum, triggering calcium release from the stores. This triggers further effects, primarily through the activation of an enzyme Protein Kinase C. This enzyme, as a kinase, functions by phosphorylation of other enzymes causing their activation, or by phosphorylation of certain channels leading to the increase or decrease of electrolyte transfer in or out of the cell.
During exercise, α1-adrenergic receptors in active muscles are attenuated in an exercise intensity-dependent manner, allowing the β2-adrenergic receptors which mediate vasodilation to dominate.[18] In contrast to α2-adrenergic receptors, α1-adrenergic-receptors in the arterial vasculature of skeletal muscle are more resistant to inhibition, and attenuation of α1-adrenergic-receptor-mediated vasoconstriction only occurs during heavy exercise.[18]
Note that only active muscle α1-adrenergic receptors will be blocked. Resting muscle will not have its α1-adrenergic receptors blocked, and hence the overall effect will be α1-adrenergic-mediated vasoconstriction.[citation needed]
^Piascik MT, Perez DM (August 2001). "Alpha1-adrenergic receptors: new insights and directions".The Journal of Pharmacology and Experimental Therapeutics.298 (2):403–10.PMID11454900.
^abcRang HP (2003).Pharmacology. Edinburgh: Churchill Livingstone.ISBN978-0-443-07145-4. Page 163
^Le, Tao; Bhushan, Vikas; Sochat, Matthew (2021).First Aid for the USMLE Step 1 2021:A Student to Student Guide. McGraw Hill. p. 240.ISBN978-1-260-46752-9.
^Chou EC, Capello SA, Levin RM, Longhurst PA (December 2003). "Excitatory alpha1-adrenergic receptors predominate over inhibitory beta-receptors in rabbit dorsal detrusor".The Journal of Urology.170 (6 Pt 1):2503–7.doi:10.1097/01.ju.0000094184.97133.69.PMID14634460.
^Cheng JT, Kuo DY (August 2003). "Both alpha1-adrenergic and D(1)-dopaminergic neurotransmissions are involved in phenylpropanolamine-mediated feeding suppression in mice".Neuroscience Letters.347 (2):136–8.doi:10.1016/S0304-3940(03)00637-2.PMID12873745.S2CID24284964.
^Dinh L, Nguyen T, Salgado H, Atzori M (November 2009). "Norepinephrine homogeneously inhibits alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate- (AMPAR-) mediated currents in all layers of the temporal cortex of the rat".Neurochemical Research.34 (11):1896–906.doi:10.1007/s11064-009-9966-z.PMID19357950.S2CID25255160.
^Wang GY, McCloskey DT, Turcato S, Swigart PM, Simpson PC, Baker AJ (October 2006). "Contrasting inotropic responses to alpha1-adrenergic receptor stimulation in left versus right ventricular myocardium".American Journal of Physiology. Heart and Circulatory Physiology.291 (4): H2013-7.doi:10.1152/ajpheart.00167.2006.PMID16731650.S2CID20464280.
^Moro C, Tajouri L, Chess-Williams R (January 2013). "Adrenoceptor function and expression in bladder urothelium and lamina propria".Urology.81 (1): 211.e1–7.doi:10.1016/j.urology.2012.09.011.PMID23200975.
^abBoron WF (2005).Medical Physiology: A Cellular And Molecular Approaoch. Elsevier/Saunders.ISBN978-1-4160-2328-9. Page 787
^Timmermans PB, de Jonge A, Thoolen MJ, Wilffert B, Batink H, van Zwieten PA (April 1984). "Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists".Journal of Medicinal Chemistry.27 (4):495–503.doi:10.1021/jm00370a011.PMID6142954.